Insulet Corp
GOV
Company Profile
Business description
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Contact
100 Nagog Park
ActonMA01720
USAT: +1 978 600-7000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
5,400
Stocks News & Analysis
stocks
Is this the catalyst US tech giant needs?
Muse models may just be the spark that the rirm needed in AI model development.
stocks
ASX share plunges due to Iran related weakness
Despite headwinds our long-term outlook is unchanged.
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,105.20 | 1.80 | -0.02% |
| CAC 40 | 8,259.60 | 13.81 | 0.17% |
| DAX 40 | 23,803.95 | 3.04 | -0.01% |
| Dow JONES (US) | 47,916.57 | 269.23 | -0.56% |
| FTSE 100 | 10,600.53 | 2.95 | -0.03% |
| HKSE | 25,536.90 | 356.64 | -1.38% |
| NASDAQ | 22,902.89 | 80.48 | 0.35% |
| Nikkei 225 | 56,357.40 | 566.71 | -1.00% |
| NZX 50 Index | 12,988.09 | 193.35 | -1.47% |
| S&P 500 | 6,816.89 | 7.77 | -0.11% |
| S&P/ASX 200 | 8,917.20 | 5.40 | 0.06% |
| SSE Composite Index | 3,975.93 | 10.29 | -0.26% |